Glenmark Pharma

{
  "main_header": {
    "sid": 780863,
    "name": "Glenmark Pharma",
    "stock_name": "Glenmark Pharma",
    "full_name": "Glenmark Pharmaceuticals Ltd.",
    "name_url": "stocks-analysis/glenmark-pharma",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,450.00",
    "chg": 2.6,
    "chgp": "0.11%",
    "dir": 1,
    "prev_price": "2,447.40",
    "mcapval": "69,698.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": 532296,
    "symbol": "GLENMARK",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE935A01035",
    "curr_date": "Sep 21, 03:30 PM",
    "curr_time": "18:16 PM",
    "last_traded_at": "Sep 21, 03:30 PM IST",
    "bse_nse_vol": "4.2 lacs",
    "exc_status": "Active",
    "traded_date": "Sep 21, 2026",
    "traded_date_str": "2026 09 21",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glenmark-pharma-780863-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "text": "Part of MojoOne Strategy",
      "type": "SM",
      "url": "https://www.marketsmojo.com/mojopro/stock-of-the-month",
      "ismore": 0,
      "all_data": [],
      "is_blur": 1,
      "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glenmark-pharma-780863-1&utm_source=Spage_Score_PartofStrategies"
    }
  },
  "news": {
    "results": [
      {
        "title": "Glenmark Pharmaceuticals Ltd. is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glenmark-pharmaceuticals-ltd-is-rated-hold-4197892",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/GlenmarkPharmac_mojoScore_4197892.png",
        "date": "2026-09-19 10:10:34",
        "description": "Glenmark Pharmaceuticals Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Glenmark Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-signals-4194185",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/GlenmarkPharmac_technicaldot_4194185.png",
        "date": "2026-09-16 08:06:54",
        "description": "Glenmark Pharmaceuticals Ltd. has experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish stance as of mid-September 2026. Despite a day decline of 1.74%, the stock’s broader technical indicators present a nuanced picture, with some signals maintaining strength while others suggest caution. This article analyses the recent technical parameter changes, price momentum, and key indicator readings to provide a comprehensive view for investors."
      },
      {
        "title": "Glenmark Pharmaceuticals Ltd. is Rated Buy",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glenmark-pharmaceuticals-ltd-is-rated-buy-4186382",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/GlenmarkPharmac_mojoScore_4186382.png",
        "date": "2026-09-08 10:10:51",
        "description": "Glenmark Pharmaceuticals Ltd. is rated 'Buy' by MarketsMOJO, with this rating last updated on 26 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 September 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Glenmark Pharmaceuticals Gains 9.17%: 7 Key Factors Driving the Rally",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-gains-917-7-key-factors-driving-the-rally-4174494",
        "imagepath": "",
        "date": "2026-08-29 16:01:04",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>24 Aug:</strong> Sharp open interest surge amid bullish market signals</p>\n                    <p><strong>27 Aug:</strong> New 52-week and all-time high at Rs.2,483.30</p>\n                    <p><strong>26 Aug:</strong> Upgrade to Buy rating on strong technicals and valuation appeal</p>\n                    <p><strong>28 Aug:</strong> New 52-week and all-time high at Rs.2,493.10</p>\n                    <p><strong>28 Aug:</strong> Week closes at Rs.2,517.40 (+9.17%) outperforming Sensex</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.2,306.00</div></div>\n ..."
      },
      {
        "title": "Broad-Based Technical Strength Lifts Glenmark Pharmaceuticals Ltd. to 52-Week High of Rs 2493.1",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-hits-new-52-week-high-at-rs24931-4173660",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/GlenmarkPharmac_priceRelatedfactors_4173660.png",
        "date": "2026-08-28 13:35:38",
        "description": "Surging past its previous peaks, Glenmark Pharmaceuticals Ltd. reached a fresh 52-week high of Rs 2493.1 on 28 Aug 2026, marking a significant milestone in its price momentum. This rally has been underpinned by a confluence of robust technical indicators and sustained buying interest, setting the stage for a compelling momentum narrative."
      },
      {
        "title": "Strong Momentum Meets Stretched Valuations as Glenmark Pharmaceuticals Ltd. Reaches All-Time High",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-stock-hits-all-time-high-on-28-aug-2026-4173652",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/GlenmarkPharmac_priceRelatedfactors_4173652.png",
        "date": "2026-08-28 13:22:46",
        "description": ""
      },
      {
        "title": "Broad-Based Technical Strength Lifts Glenmark Pharmaceuticals Ltd. to 52-Week High of Rs 2483.3",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-hits-new-52-week-high-at-rs24833-4171180",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/GlenmarkPharmac_priceRelatedfactors_4171180.png",
        "date": "2026-08-27 09:46:27",
        "description": "With a decisive break above Rs 2483.3 on 27 Aug 2026, Glenmark Pharmaceuticals Ltd. has reached a fresh 52-week and all-time high, propelled by a confluence of strong technical indicators and sustained price momentum despite a broadly subdued market backdrop."
      },
      {
        "title": "Strong Momentum Meets Stretched Valuations as Glenmark Pharmaceuticals Ltd. Reaches All-Time High",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-stock-hits-all-time-high-at-rs-248330-4171124",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/GlenmarkPharmac_priceRelatedfactors_4171124.png",
        "date": "2026-08-27 09:34:12",
        "description": ""
      },
      {
        "title": "Glenmark Pharmaceuticals Upgraded to Buy on Strong Technicals and Valuation Appeal",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glenmark-pharmaceuticals-upgraded-to-buy-on-strong-technicals-and-valuation-appeal-4171018",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/GlenmarkPharmac_mojoScore_4171018.png",
        "date": "2026-08-27 08:22:25",
        "description": "Glenmark Pharmaceuticals Ltd. has seen its investment rating upgraded from Hold to Buy, reflecting improved technical indicators, attractive valuation, solid financial trends, and enhanced quality metrics. The mid-cap pharmaceutical company’s recent performance and market positioning have prompted analysts to revise their outlook, signalling renewed investor confidence amid a challenging sector backdrop."
      }
    ],
    "total": 618,
    "sid": "780863",
    "stock_news_url": "https://www.marketsmojo.com/news/glenmark-pharmaceuticals-780863"
  },
  "announcements": [
    {
      "details": "Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 26, 2019, titled \"Glenmark Pharmaceuticals receives ANDA approval for Metformin Hydrochloride Extended-Release Tablets USP,",
      "source": "NSE",
      "caption": "Glenmark Pharmaceuticals Limited - Press Release",
      "datetime": "26-Nov-2019"
    },
    {
      "details": "Glenmark Pharmaceuticals Limited has informed the Exchange regarding Grant of 20000 Options.",
      "source": "NSE",
      "caption": "Glenmark Pharmaceuticals Limited - ESOP/ESOS/ESPS",
      "datetime": "15-Nov-2019"
    },
    {
      "details": "Glenmark Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015",
      "source": "NSE",
      "caption": "Glenmark Pharmaceuticals Limited - Trading Window",
      "datetime": "06-Nov-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has declared <strong>250%</strong> dividend, ex-date: 31 Aug 26",
          "dt": "2026-08-31",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has announced <strong>1:2</strong> stock split, ex-date: 10 Sep 07",
          "dt": "2007-09-10",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Glenmark Pharmaceuticals Ltd. is Rated Hold

2026-09-19 10:10:34

Glenmark Pharmaceuticals Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Glenmark Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Signals

2026-09-16 08:06:54

Glenmark Pharmaceuticals Ltd. has experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish stance as of mid-September 2026. Despite a day decline of 1.74%, the stock’s broader technical indicators present a nuanced picture, with some signals maintaining strength while others suggest caution. This article analyses the recent technical parameter changes, price momentum, and key indicator readings to provide a comprehensive view for investors.

Read full news article

Glenmark Pharmaceuticals Ltd. is Rated Buy

2026-09-08 10:10:51

Glenmark Pharmaceuticals Ltd. is rated 'Buy' by MarketsMOJO, with this rating last updated on 26 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 September 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Glenmark Pharmaceuticals Gains 9.17%: 7 Key Factors Driving the Rally

2026-08-29 16:01:04

Key Events This Week

24 Aug: Sharp open interest surge amid bullish market signals

27 Aug: New 52-week and all-time high at Rs.2,483.30

26 Aug: Upgrade to Buy rating on strong technicals and valuation appeal

28 Aug: New 52-week and all-time high at Rs.2,493.10

28 Aug: Week closes at Rs.2,517.40 (+9.17%) outperforming Sensex

Week Open

Rs.2,306.00

...

Read full news article

Broad-Based Technical Strength Lifts Glenmark Pharmaceuticals Ltd. to 52-Week High of Rs 2493.1

2026-08-28 13:35:38

Surging past its previous peaks, Glenmark Pharmaceuticals Ltd. reached a fresh 52-week high of Rs 2493.1 on 28 Aug 2026, marking a significant milestone in its price momentum. This rally has been underpinned by a confluence of robust technical indicators and sustained buying interest, setting the stage for a compelling momentum narrative.

Read full news article

Strong Momentum Meets Stretched Valuations as Glenmark Pharmaceuticals Ltd. Reaches All-Time High

2026-08-28 13:22:46

Read full news article

Broad-Based Technical Strength Lifts Glenmark Pharmaceuticals Ltd. to 52-Week High of Rs 2483.3

2026-08-27 09:46:27

With a decisive break above Rs 2483.3 on 27 Aug 2026, Glenmark Pharmaceuticals Ltd. has reached a fresh 52-week and all-time high, propelled by a confluence of strong technical indicators and sustained price momentum despite a broadly subdued market backdrop.

Read full news article

Strong Momentum Meets Stretched Valuations as Glenmark Pharmaceuticals Ltd. Reaches All-Time High

2026-08-27 09:34:12

Read full news article

Glenmark Pharmaceuticals Upgraded to Buy on Strong Technicals and Valuation Appeal

2026-08-27 08:22:25

Glenmark Pharmaceuticals Ltd. has seen its investment rating upgraded from Hold to Buy, reflecting improved technical indicators, attractive valuation, solid financial trends, and enhanced quality metrics. The mid-cap pharmaceutical company’s recent performance and market positioning have prompted analysts to revise their outlook, signalling renewed investor confidence amid a challenging sector backdrop.

Read full news article

View All News